Avidity Biosciences, Inc. (RNA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sarah Boyce
Employees:
190
10975 N. TORREY PINES RD.,, #150, LA JOLLA, CA 92037
858-41-7900

Avidity Biosciences, Inc. engages in the development of oligonucleotide-based therapies. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the. treatment of Duchenne Muscular Dystrophy.

Data derived from most recent annual or quarterly report
Market Cap 578.691 Million Shares Outstanding74.096 Million Avg 30-day Volume 1.807 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.71
Price to Revenue46.6396 Debt to Equity0.0135 EBITDA-229.556 Million
Price to Book Value0.9136 Operating Margin-2191.0024 Enterprise Value-62.865 Million
Current Ratio11.403 EPS Growth0.085 Quick Ratio11.138
1 Yr BETA 0.8682 52-week High/Low 25.74 / 4.83 Profit Margin-1995.3433
Operating Cash Flow Growth-41.7376 Free Cash Flow to Firm (FCFF) TTM -157.952 Million Free Cash Flow to Equity (FCFE) TTM-159.671 Million
Altman Z-Score3.6434
Earnings Report2024-02-27

Are you looking for these stocks instead?

View SEC Filings from RNA instead.

View recent insider trading info

Avidity Biosciences, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RNA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RNA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-12 by BOYCE SARAH
  • 4: filed on 2023-09-12 by MCCARTHY TERESA
  • 4: filed on 2023-09-12 by FLANAGAN W. MICHAEL
  • 4: filed on 2023-06-20 by MOSBROOKER ERIC
  • 4: filed on 2023-06-20 by KIM JEAN JINSUN
  • 4: filed on 2023-06-20 by HENIG NOREEN
  • 4: filed on 2023-06-20 by THOMPSON TAMAR
  • 4: filed on 2023-03-17 by LEVIN ARTHUR A
  • 4: filed on 2023-02-03 by BOYCE SARAH
  • 4: filed on 2023-01-03 by LEVIN ARTHUR A

    • Events (8k)

  • 8-K: filed on 2023-11-28:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-10:
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-10:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
  • 8-K: filed on 2023-06-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-17:
    Item 8.01: Other Events
  • 8-K: filed on 2023-04-27:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-30:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MACLEAN MICHAEL F CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-09-11 2

    BOYCE SARAH PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-09-11 3

    FLANAGAN W. MICHAEL CSTO

    • Officer
    		 0 2023-09-11 2

    MCCARTHY TERESA CHIEF HUMAN RESOURCES OFFICER

    • Officer
    		 0 2023-09-11 2

    BOESS CARSTEN

    • Director
    		 0 2023-06-15 1

    KAYE EDWARD M. MD

    • Director
    		 0 2023-06-15 1

    WILSON TROY EDWARD

    • Director
    		 0 2023-06-15 1

    MOSBROOKER ERIC

    • Director
    		 0 2023-06-15 1

    HENIG NOREEN

    • Director
    		 0 2023-06-15 1

    THOMPSON TAMAR

    • Director
    		 0 2023-06-15 1

    KIM JEAN JINSUN

    • Director
    		 0 2023-06-15 1

    LEVIN ARTHUR A

    • Director
    		 293,202 2023-03-15 5

    RTW INVESTMENTS, LP

    WONG RODERICK MP AND CIO

    • Officer
    • 10% Owner
    		 4,795,000 2021-08-04 0

    WONG RODERICK

    • Director
    • 10% Owner
    		 15,000 2021-06-16 0

    BAROLDI JOSEPH CHIEF OPERATING OFFICER

    • Officer
    		 0 2021-02-02 0

    KIM JAE B. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2021-02-02 0

    EDWARDS MARTIN

    • Director
    		 136,776 2021-01-01 0

    ELI LILLY & CO

    • 10% Owner
    		 2,169,396 2020-06-16 0

    CORMORANT ASSET MANAGEMENT, LP

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    CORMORANT PRIVATE HEALTHCARE FUND II, LP

    • Director
    • 10% Owner
    • FORMER 10% OWNER
    		No longer subject to file 2020-06-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 19:45:03 UTC 4.875 0.445 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 19:15:04 UTC 4.875 0.445 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 18:45:04 UTC 4.875 0.445 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 18:15:04 UTC 4.875 0.445 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 17:45:04 UTC 4.875 0.445 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 17:15:04 UTC 4.875 0.445 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 16:45:03 UTC 4.9119 0.4081 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 16:15:04 UTC 4.9119 0.4081 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 15:45:04 UTC 4.9119 0.4081 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 15:15:04 UTC 4.9119 0.4081 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 14:45:04 UTC 4.9631 0.3569 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 14:15:04 UTC 4.9631 0.3569 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 13:45:04 UTC 4.6526 0.6674 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 13:15:04 UTC 4.6526 0.6674 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-30 12:45:03 UTC 4.6526 0.6674 2600000
    AVIDITY BIOSCIENCES INC RNA 2023-11-29 22:15:05 UTC 4.6529 0.6671 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-29 21:45:04 UTC 4.6529 0.6671 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-29 21:15:05 UTC 4.6529 0.6671 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-29 20:45:04 UTC 4.6529 0.6671 2400000
    AVIDITY BIOSCIENCES INC RNA 2023-11-29 20:15:03 UTC 4.6529 0.6671 2400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund RNA -5342.0 shares, $-87234.86 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments